Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05774080 · ClinicalTrials.gov registry record

An Observational Study of Patients With Chronic Gastrointestinal Disease

A clinical trial of Gastrointestinal Diseases, sponsored by Target PharmaSolutions.

Active
Registry status
500,000
Enrollment target
1
Study location

NCT05774080 is a study of Gastrointestinal Diseases that is active but no longer recruiting, run by Target PharmaSolutions. The registered enrollment target is 500,000 participants, above the 703-participant average among 14 other Gastrointestinal Diseases trials with a reported enrollment target (71024% higher). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05774080, a study of Gastrointestinal Diseases, is active but no longer recruiting, sponsored by Target PharmaSolutions.

ACTIVE NOT RECRUITING
Registry status
500,000 participants
Enrollment target
1
Study location

Study Summary

TARGET-GASTRO is an observational research study to conduct a comprehensive review of outcomes for patients with the chronic gastrointestinal (GI) diseases: eosinophilic gastrointestinal disease (EGID), ulcerative colitis (UC) or Crohn's disease (CD).

Conditions Studied

Interventions

  • OTHER Observational

Study Locations (1)

North Carolina

  • Atrium Health/Wake Forest University School of Medicine - Winston-Salem

Trial Details

FieldValue
Enrollment Target 500,000 participants
Start Date 2023-08-01
Est. Completion 2037-12

Sponsor

Target PharmaSolutions

10 total trials

What the Registry Record Tells You About NCT05774080

The ClinicalTrials.gov registry entry for NCT05774080 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 500,000 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 703-participant average among 14 other Gastrointestinal Diseases trials with a reported enrollment target (71024% higher). The listed sponsor is Target PharmaSolutions, which has 10 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Gastrointestinal Diseases appearing as the primary indexed condition, and to 1 intervention - of which Observational is the first listed.

NCT05774080 reports 1 study location spanning 1 distinct geographic area - top geographies include North Carolina.

Frequently Asked Questions

What is clinical trial NCT05774080 about?

NCT05774080 is a clinical study titled "An Observational Study of Patients With Chronic Gastrointestinal Disease". TARGET-GASTRO is an observational research study to conduct a comprehensive review of outcomes for patients with the chronic gastrointestinal (GI) diseases: eosinophilic gastrointestinal disease (EGID), ulcerative colitis (UC) or Crohn's disease (CD).

What is the current status of trial NCT05774080?

This trial is currently active not recruiting. The enrollment target is 500,000 participants. The study started on 2023-08-01. Estimated completion is 2037-12.

What conditions does trial NCT05774080 study?

This clinical trial studies the following conditions: Gastrointestinal Diseases.

What interventions are being tested in trial NCT05774080?

The interventions under investigation include: Observational (OTHER).

Who is sponsoring clinical trial NCT05774080?

This trial is sponsored by Target PharmaSolutions, which has 10 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05774080 being conducted?

This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Gastrointestinal Diseases

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.